M1166 HCPCS Level II Code: Pathology report for tissue specimens produced from wide local excisions or re-excisions
Medicare Coverage & Payment
- Medicare coverage: Carrier judgment (CMS coverage code C)
- Payment category: Service not separately priced (pricing indicator 00)
- BETOS: Z2 — Undefined codes
- Last CMS action effective: January 1, 2023
Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.
Official Registry Overview & Definition
Pathology report for tissue specimens produced from wide local excisions or re-excisions is a HCPCS Level II code (M1166). CMS assigns coverage code C — Carrier judgment. Short description: Path rpt tis spec wle/reexc.
Nearest Codes in This Family
Official HCPCS Level II classifications closest to M1166 in its code family, with their registry titles.
- M1161 — Patient had anaphylaxis due to the tetanus, diphtheria or pertussis vaccine any time on or before the patient's 13th birthday
- M1162 — Patient had encephalitis due to the tetanus, diphtheria or pertussis vaccine any time on or before the patient's 13th birthday
- M1163 — Patient had anaphylaxis due to the hpv vaccine any time on or before the patient's 13th birthday
- M1164 — Patients with dementia any time during the patient's history through the end of the measurement period
- M1165 — Patients who use hospice services any time during the measurement period
- M1167 — In hospice or using hospice services during the measurement period
- M1168 — Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period
- M1169 — Documentation of medical reason(s) for not administering influenza vaccine (e.g., prior anaphylaxis due to the influenza vaccine)
- M1170 — Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period
- M1171 — Patient received at least one td vaccine or one tdap vaccine between nine years prior to the encounter and the end of the measurement period